Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- CEA Process to Be Improved, but Operational Issues Remain: PhRMA/EFPIA
January 20, 2022
- JGA Chief Pledges to Restore Trust in Generics in 2022
January 14, 2022
- JPA Urges MHLW to Allow Access to List of Registered Pharmacies Carrying Lagevrio
January 14, 2022
- Osamu Kunii of Global Fund to Become New GHIT Fund CEO
January 13, 2022
- FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief
January 6, 2022
- EFPIA Japan Taps Takeo Morooka as Director General
December 24, 2021
- Generic Use Rate Skids to 79.2% in July-September: JGA
December 24, 2021
- Japan Trade Groups Hail Progress in Reward for Innovation, but Fret Cost Disclosure Plans: FY2022 Reform
December 23, 2021
- INES Launches Cervical Cancer Awareness Project in Japan
December 10, 2021
- Study Group Launched by Drug Policy Veterans Pushes 6% Adjustment Rate
December 6, 2021
- JEMA Calls for Disclosure of Expected 3-Month Inventory Levels, Smaller Number of Companies per API
December 2, 2021
- Pharma, Wholesaler Leaders Hold 1st Meeting with PM Kishida
November 30, 2021
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
- JPMA Director Gets Sarcastic on MOF’s Data Presentation on Drug Costs
November 19, 2021
- Sales Reps in Japan Log Record Decline in FY2020, Down for 7 Consecutive Years
November 17, 2021
- Plaintiffs, Lawyers Re-Stress Opposition to HPV Vaccine Recommendation
November 15, 2021
- JPWA Vows to Boost Compliance after New Bid-Rigging Probe
November 12, 2021
- Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
- Japan No. 3 Originator Country in Global Top 100 Drug List in 2020: JPMA Think Tank
November 11, 2021
- PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
October 29, 2021
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…